Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
Early phase 1: Dream Yoga Inspired Intervention for Anxiety
People spend approximately one-third of their lives asleep, yet sleep is often underused as an opportunity to support psychological well-being. Contemplative traditions, including Tibetan Dream Yoga, have developed practices that use waking imagination and lucid dreaming to explore perception, awareness, and habitual patterns of thinking.
Phase 1: the first tests in people. The main question is safety and dose, not whether it cures the condition. Groups are small. Side effects are watched closely.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
If you join, the listed intervention(s) are Dream Yoga Inspired Intervention, or Sleep Health Enhancement Program (SHEP). The registry lists allocation as randomized. People spend approximately one-third of their lives asleep, yet sleep is often underused as an opportunity to support psychological well-being.
They plan to enroll about 70 people at 2 sites. Taking part typically means following a program (exercise, therapy, diet, or an app) plus check-ins.
Official title (unrewritten)
Transformative Benefits of Contemplative Sleep Practices and a Novel Pathway to Deliver Benefits to the General Public
Interventions: Dream Yoga Inspired Intervention, Sleep Health Enhancement Program (SHEP)
Primary outcome (registry wording): Changes in frontal midline theta
Who it is for (from inclusion criteria)
Ages 18 Years to any
Individuals interested in participating will be screened for eligibility through a Qualtrics survey, a Score between 5-21 points in GAD-7
Healthy, English-speaking adults (at least 18 years old) with high dream recall (at least 1/week)
Who the registry excludes
We will exclude people who self-report any of the following:
history of an established meditative practice
psychological or psychiatric disorders (other than mild anxiety)
sleep disorders, nightshift work in the past month, extreme chronotype or irregular sleeping pattern
We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled.
This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.
This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT07408206?
Early phase 1. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT07408206?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.